Pradhan, Jaya Prakash (2007): New Policy Regime and Small Pharmaceutical Firms in India.
Download (627kB) | Preview
Small firms dominate the Indian pharmaceutical industry with significant contribution to the national drug production and employment. They had played an important role in enhancing domestic technological capabilities in drugs production and have been instrumental in keeping drugs prices affordable for the Indian populace in remote rural areas. This rise of small firms in this sector has been facilitated by a set of strategic government polices implemented in the past decades like adoption of a process patent regime, relaxation granted from price control and industrial licensing requirement, reservation of items for exclusive production and preference in government procurement, etc. Since 1990s the regulatory regime for small firms underwent dramatic changes with withdrawal of most of the favoruable policies and implementation of regulations like a long‐term product patent regime, withdrawal of exemption from price controls, implementation of good manufacturing practices, etc. These new policies have a number of implications for the survival and growth of small pharmaceutical firms today.
|Item Type:||MPRA Paper|
|Original Title:||New Policy Regime and Small Pharmaceutical Firms in India|
|Keywords:||Small Firms; TRIPS; Patent|
|Subjects:||F - International Economics > F1 - Trade > F13 - Trade Policy ; International Trade Organizations
L - Industrial Organization > L1 - Market Structure, Firm Strategy, and Market Performance > L11 - Production, Pricing, and Market Structure ; Size Distribution of Firms
O - Economic Development, Innovation, Technological Change, and Growth > O3 - Innovation ; Research and Development ; Technological Change ; Intellectual Property Rights > O34 - Intellectual Property and Intellectual Capital
|Depositing User:||Dr. Jaya Prakash Pradhan|
|Date Deposited:||23. Dec 2008 13:08|
|Last Modified:||16. Mar 2015 03:18|
Business Standard (2006), ‘Chinese drugs pose threat to Indian pharma’, December 12.
Das, K and Nair, T.S. (2004), ‘Global Regulatory Imperatives and Small Firms: The Case of Indian Pharmaceuticals’, in Pietrobelli and Sverrisson edited Linking Local and Global Economics: the Ties that Bind, Routledge, London, pp. 240–253.
Das, K 2006), ‘Micro and Small Enterprises during Reforms: Policy and Concerns’, GIDR Working Paper No. 171, Gujarat Institute of Development Research, Ahmedabad.
Express Pharma Pulse (2005), ‘SSIs protest against MRP‐based excise duty’, June 09.
Kumar, N. and Pradhan, J.P. (2003), ‘Economic Reforms, WTO and Indian Drugs and Pharmaceuticals Industry: Implications of Emerging Trends’, CMDR Monograph Series, No. 42, The Centre for Multidisciplinary Development Research, Dharwad, India.
OECD (2001), OECD Science, Technology and Industry Scoreboard 2001—Towards a knowledgebased economy.
Pharmabiz (2006), ‘Hostile environs force small firms flee’, May 04.
Pradhan (2002), ‘Liberalization, Firm Size and R&D Performance: A Firm Level Study of Indian Pharmaceutical Industry’, Indian Journal of Political Economy, Vol. XIV, No. 4, pp. 647–666.
Pradhan, J.P. (2006), ‘Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies’, ISID Working Paper, No. WP2006/05.
Pradhan, J.P. and Alakshendra, A. (2006), ‘Overseas Acquisition versus Greenfield Foreign Investment: Which Internationalization Strategy is better for Indian Pharmaceutical Enterprises?’ ISID Working Paper, No. WP2006/07.
Tribune (2006), ‘Drug manufacturers resent tax holiday in 3 states’, September 05.